Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Twist Bioscience Corporation (NASDAQ: TWST) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a mid-cap growth and value biotech company focused on synthetic DNA tools and a silicon-based DNA synthesis platform, Twist uses its filings to report financial performance, governance changes and other material events.
Investors can review current and historical 8-K reports, which for Twist have included announcements of quarterly and full-year financial results, as well as board and committee changes. For example, recent 8-K filings describe the release of financial results for specific quarters and fiscal years, and the appointment of a new director to the board and audit committee, along with associated compensation arrangements.
In addition to 8-Ks, users can access Twist’s annual reports on Form 10-K and quarterly reports on Form 10-Q via the SEC feed. These documents typically contain detailed discussions of results of operations, risk factors, and business descriptions related to Twist’s synthetic DNA platform, research tools and geographic operations. Proxy materials and equity compensation plan disclosures can also be reviewed to understand governance practices and incentive structures.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, helping readers quickly interpret complex documents such as lengthy 10-Ks or detailed 10-Qs. Real-time updates from EDGAR ensure that new filings appear promptly, while Form 4 and related insider transaction reports can be monitored to see equity awards and other reportable insider activity. Together, these resources support a deeper understanding of TWST’s regulatory disclosures and corporate developments.
Twist Bioscience Corp’s President and COO Patrick John Finn reported option exercises and share sales in a pre-planned trading program. On February 12 and 13, 2026, he exercised multiple stock options for common stock at exercise prices of $23.33 and $26.66 per share, converting them into ordinary shares. Over the same two days, he sold 3,500 and 1,750 shares of common stock in open-market transactions at weighted average prices of about $50.225 and $50.041 per share, with individual sale prices ranging from $50.00 to $50.51. All transactions were executed under a Rule 10b5-1 trading plan adopted on May 13, 2025, and he held 306,250 common shares directly after the reported trades, along with remaining vested stock options.
EdgePoint Investment Group Inc. reported a significant ownership position in Twist Bioscience Corp common stock. As of December 31, 2025, EdgePoint beneficially owned 5,377,991 shares, representing 8.80% of the outstanding common stock.
EdgePoint, an investment adviser based in Ontario, Canada, has sole voting and dispositive power over 4,165,651 shares and shared voting and dispositive power over 1,212,340 shares. The stake is held in the ordinary course of business and not for the purpose of changing or influencing control of Twist Bioscience.
Twist Bioscience Corporation has filed a prospectus supplement registering up to 632,328 shares of common stock for resale by existing selling securityholders. These shares are issuable under Stock Purchase Agreements dated February 11, 2026, and may be sold over time in various types of negotiated or market transactions.
The selling securityholders, including Invenra Inc. and other smaller holders, will receive all proceeds from any share sales, while Twist will receive no proceeds from these resales and will only cover registration-related expenses. The company’s common stock trades on the Nasdaq Global Select Market under the symbol TWST.
Twist Bioscience Corporation entered into stock purchase agreements with Invenra Inc. and two of Invenra’s investors. Twist will issue up to 632,328 shares of common stock. Up to 324,558 shares plus $5 million in cash will be provided to Invenra in exchange for a license agreement and certain technology. Twist will also issue up to 307,770 shares to two Invenra investors in exchange for preferred stock, giving Twist approximately a 6% ownership stake in Invenra. Twist gains the right to designate one director to Invenra’s board, whose members, including the Twist designee, may approve two additional directors. The company simultaneously granted registration rights and is filing a prospectus supplement to register the resale of these shares.
Twist Bioscience chief financial officer Adam Laponis sold 7,000 shares of common stock in an open-market transaction at $50 per share on February 12, 2026. After this planned sale under a previously adopted Rule 10b5-1 trading plan, he directly holds 130,031 shares.
Patrick Finn has filed a notice of proposed sale of restricted securities, indicating an intent to sell 1,750 shares of common stock of TWST through Fidelity Brokerage Services LLC. The planned sale, listed for 02/13/2026 on NASDAQ, has an aggregate market value of 87572.02. Shares of the issuer outstanding were 61,311,704 at the time referenced.
The shares to be sold were recently acquired through option exercises dated 11/19/2018 and 10/24/2019 (settled on 02/13/2026) totaling 1,212 shares for cash, and 538 shares from restricted stock vesting on 11/05/2024 as compensation. Over the past three months, Finn has already sold multiple common stock blocks, including 23,279 shares for gross proceeds of 931160.00 on 01/13/2026 and 3,500 shares for 175789.05 on 02/12/2026.
Twist Bioscience Corp executive Dennis Cho reported an open-market sale of company stock. On February 11, 2026, he sold 5,000 shares of common stock at a price of $49.93 per share. After this transaction, he directly owned 138,581 shares.
The filing notes that this sale was carried out under a Rule 10b5-1 trading plan that Cho had previously adopted on May 7, 2025. He serves as Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience, indicating the transaction involves a senior member of management.
Twist Bioscience received a notice that a holder plans to sell 2,184 shares of its common stock on or about 02/13/2026. The shares, with an aggregate market value of $105,401.37, will be sold through Fidelity Brokerage Services LLC on the NASDAQ exchange.
The securities were acquired on 02/05/2026 via restricted stock vesting from the issuer as compensation. As of the filing, there were 61,311,704 common shares outstanding, which is a baseline figure and not the amount being sold.
Patrick Finn filed a notice to sell up to 3,500 shares of Twist Bioscience common stock under Rule 144. The filing lists an aggregate market value of 175,789.00 for these shares, to be sold through Fidelity Brokerage Services LLC on NASDAQ.
The shares come from option grants dated 11/19/2018 and 10/24/2019 totaling 2,500 shares, and 1,000 shares from restricted stock vesting on 11/08/2024. Recent activity also shows separate sales, including 23,279 shares on 01/13/2026 for gross proceeds of 931,160.00.
Adam Laponis filed a Form 144 indicating an intent to sell up to 7,000 shares of Twist Bioscience common stock. The planned sale through Fidelity Brokerage Services on NASDAQ has an aggregate market value of 350000.00. Twist Bioscience had 61,311,704 common shares outstanding.
The shares to be sold were acquired through restricted stock vesting from the issuer on 10/01/2025, 10/08/2025, and 10/29/2025, totaling 6,, , , , , 614, 2,170, and 4,216 shares as compensation.